Dr. Surena Matin discusses significance of OLYMPUS trial, Jelmyto


“[Low-grade upper tract urothelial carcinoma] is fairly uncommon, yet it’s common enough that every urologist comes across it,” says Surena F. Matin, MD.

In this video, Surena F. Matin, MD, discusses the significance of the OLYMPUS trial of mitomycin-containing reverse thermal hydrogel (Jelmyto) for low-grade upper tract urothelial carcinoma and how the treatment addresses an unmet therapeutic need. Final results of the OLYMPUS trial were presented at the 2020 Society of Urologic Oncology annual meeting. Matin is a professor urology at the University of Texas MD Anderson Cancer Center, Houston.

Recent Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.